Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 4
2004 2
2005 3
2006 3
2007 5
2008 2
2009 4
2010 5
2011 3
2012 4
2013 8
2014 2
2015 4
2016 5
2017 6
2018 6
2019 4
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

73 results
Results by year
Filters applied: . Clear all
Page 1
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.
Sarhan D, Brandt L, Felices M, Guldevall K, Lenvik T, Hinderlie P, Curtsinger J, Warlick E, Spellman SR, Blazar BR, Weisdorf DJ, Cooley S, Vallera DA, Önfelt B, Miller JS. Sarhan D, et al. Among authors: Vallera DA. Blood Adv. 2018 Jun 26;2(12):1459-1469. doi: 10.1182/bloodadvances.2017012369. Blood Adv. 2018. PMID: 29941459 Free PMC article.
Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL.
Felices M, Kodal B, Hinderlie P, Kaminski MF, Cooley S, Weisdorf DJ, Vallera DA, Miller JS, Bachanova V. Felices M, et al. Among authors: Vallera DA. Blood Adv. 2019 Mar 26;3(6):897-907. doi: 10.1182/bloodadvances.2018029371. Blood Adv. 2019. PMID: 30890546 Free PMC article.
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, Zhang B, Lenvik AJ, Panoskaltsis-Mortari A, Verneris MR, Tolar J, Cooley S, Weisdorf DJ, Blazar BR, Miller JS. Vallera DA, et al. Clin Cancer Res. 2016 Jul 15;22(14):3440-50. doi: 10.1158/1078-0432.CCR-15-2710. Epub 2016 Feb 4. Clin Cancer Res. 2016. PMID: 26847056 Free PMC article.
ImmunoPET, [64Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model.
Srideshikan SM, Brooks J, Zuro D, Kumar B, Sanchez J, Echavarria Parra L, Orellana M, Vishwasrao P, Nair I, Chea J, Poku K, Bowles N, Miller A, Ebner T, Molnar J, Rosenthal J, Vallera DA, Wong JYC, Stein AS, Colcher D, Shively JE, Yazaki PJ, Hui SK. Srideshikan SM, et al. Among authors: Vallera DA. Clin Cancer Res. 2019 Dec 15;25(24):7463-7474. doi: 10.1158/1078-0432.CCR-19-1106. Epub 2019 Sep 23. Clin Cancer Res. 2019. PMID: 31548348
Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR.
Borgatti A, Koopmeiners JS, Sarver AL, Winter AL, Stuebner K, Todhunter D, Rizzardi AE, Henriksen JC, Schmechel S, Forster CL, Kim JH, Froelich J, Walz J, Henson MS, Breen M, Lindblad-Toh K, Oh F, Pilbeam K, Modiano JF, Vallera DA. Borgatti A, et al. Among authors: Vallera DA. Mol Cancer Ther. 2017 May;16(5):956-965. doi: 10.1158/1535-7163.MCT-16-0637. Epub 2017 Feb 13. Mol Cancer Ther. 2017. PMID: 28193671 Free PMC article.
Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy.
de Witte MA, Sarhan D, Davis Z, Felices M, Vallera DA, Hinderlie P, Curtsinger J, Cooley S, Wagner J, Kuball J, Miller JS. de Witte MA, et al. Among authors: Vallera DA. Biol Blood Marrow Transplant. 2018 Jun;24(6):1152-1162. doi: 10.1016/j.bbmt.2018.02.023. Epub 2018 Mar 2. Biol Blood Marrow Transplant. 2018. PMID: 29505821 Free PMC article.
73 results
Jump to page
Feedback